Citation Tools

PDF
Original article
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation

Download to a citation manager

Cite this article as:
van Bodegraven AA, Bravenboer N, Witte BI on behalf of the Dutch Initiative on Crohn and Colitis (ICC), et al
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation